Novo Nordisk A/S
(NYSE : NVO)

( )
NVO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 3.51%40.800.9%$2343.52m
JNJJohnson & Johnson 0.47%148.140.7%$1155.49m
ABBVAbbVie, Inc. 0.86%104.931.9%$1033.67m
MRKMerck & Co., Inc. 0.34%81.830.7%$709.21m
BMYBristol-Myers Squibb Co. -0.37%62.181.0%$687.14m
LLYEli Lilly & Co. -0.27%145.171.1%$660.98m
AZNAstraZeneca Plc 0.77%53.391.2%$370.15m
TTNPTitan Pharmaceuticals, Inc. -6.65%3.510.6%$277.68m
GSKGlaxoSmithKline Plc -0.29%37.410.2%$228.11m
NVSNovartis AG 0.94%91.570.2%$204.65m
ARCTArcturus Therapeutics Holdings, Inc. 2.27%83.300.0%$101.80m
RGENRepligen Corp. -3.54%187.007.1%$97.73m
NVONovo Nordisk A/S 0.93%68.140.1%$91.58m
RPRXRoyalty Pharma Plc -2.34%41.780.2%$81.67m
CVACCureVac NV 5.69%102.660.0%$71.78m

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.